1. Name and Address of Reporting Person
Flowers Cynthia Louise

2. Issuer Name and Ticker or Trading Symbol
G1 Therapeutics, Inc. [GTHX]

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
X Director
10% Owner
Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person

Rule 10b5-1(c) Transaction Indication

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Date of Earliest Transaction (Month/Day/Year)</th>
<th>Deemed Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Amount (A) or (D)</th>
<th>Price (In $)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>06/15/2023</td>
<td>A</td>
<td>10,000(1)</td>
<td>$0.00(2)</td>
</tr>
</tbody>
</table>

(1) 10,000 RSUs from award granted on June 23, 2022; (2) 10,000 RSUs from award granted on June 15, 2023.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Date of Earliest Transaction (Month/Day/Year)</th>
<th>Deemed Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Amount (A) or (D)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title of Underlying Security (Instr. 3)</th>
<th>Price of Underlying Security on Date of Transaction (Instr. 5)</th>
<th>Number of Securities Beneficially Owned Following Report (Instr. 3 and 4)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Ownership of Indirect Beneficial Ownership (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Options (Right to Buy)</td>
<td>06/15/2023</td>
<td>A</td>
<td>30,000(1)</td>
<td>(4)</td>
<td>06/15/2023</td>
<td>Common Stock</td>
<td>$0.00</td>
<td>30,000</td>
<td>D</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 15, 2023, subject to the Reporting Person’s continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person’s service as a Director on the Company’s Board.
2. Each RSU represents a contingent right to receive one share of Issuer common stock.
3. Represents (i) 5,889 shares of common stock; (ii) 10,000 RSUs from award granted on June 23, 2022; and (iii) 10,000 RSUs from award granted on June 15, 2023.
4. The shares underlying this option will vest in their entirety twelve months after June 15, 2023, subject to the Reporting Person’s continued service as a director.

Remarks:

/A /Sandi James, attorney-in-fact 06/16/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Anne T. Leland, Brenda L. Meyette, Jacquelyn A. Cannata, Megan N. Gates, Peter N. Cunningham, Verna Krishnamurthy and Hana M. Sahdev of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., and Barclay A. Phillips, J. Stillman Hanson, Jennifer K. Moses, Becky Daniel and Sandi James of G1 Therapeutics, Inc. signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;

(3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact, on behalf of the undersigned pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 12th day of September 2018.

/s/ Cynthia L. Schwalm

Cynthia L. Schwalm